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Abstract  
Background: The objective of the study was to detect the levels of osteoprotegerin 
(OPG) and 25-hydroxyvitamin D [25(OH)D], as well as the expression of bone 
sialoprotein (BSP) mRNA, in the peripheral blood of patients with newly diagnosed 
type 2 diabetes mellitus (T2DM) under different bone mass conditions, and to explore 
its role and significance in the development process of T2DM combined with 
osteoporosis (OP). 
Material and methods: A total of 225 patients hospitalised in the Endocrinology 
Department and General Department from May 2017 to May 2018 were enrolled and 
categorised into five groups: the pure T2DM group (group A, 45 patients), the bone 
mass reduction group (group B, 45 patients), the T2DM + bone mass reduction group 
(group C, 45 patients), the OP group (group D, 45 patients), and the T2DM + OP group 
(group E, 45 patients); meanwhile, age-matched healthy subjects undergoing physical 
examination in our hospital were collected as the normal control group (group NC, 45 
cases). Logistic regression analysis was used to analyse the influencing factors of bone 
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mass in patients with T2DM. 
Results: Compared with group B, the expression levels of glycated haemoglobin 
(HbA1c), 25(OH)D, N-terminal propeptide of type I procollagen (PINP), fasting plasma 
glucose (FPG), fasting plasma insulin (FINS), high-density lipoprotein cholesterol 
(HDL-C), and BSP mRNA were significantly increased while OPG and -collagen 
degradation products (β-CTX) were significantly decreased in group A. 
Conclusions: The expression of BSP mRNA and the decrease of 25(OH)D and OPG 
in peripheral blood may participate in the development of diabetes and osteoporosis. 
 
Key words: type 2 diabetes mellitus; bone mass; bone sialoprotein; 25 hydroxy vitamin 
D; osteoprotegerin 
 
Introduction 
Diabetes mellitus (DM) is a group of metabolic diseases characterised by increased 
levels of chronic blood sugar caused by insulin secretion or defects [1]. Osteoporosis 
(OP) is a systemic bone disease characterised by decreased bone mass, decreased bone 
strength, increased bone fragility, and proneness to fracture [2]. Bone sialoprotein (BSP) 
is a marker of bone metabolism that activates osteoblasts or osteoblast-like cells, guides 
bone mineralisation, and promotes bone formation [3]. Osteoprotegerin (OPG) is a 
glycoprotein secreted by osteoblasts, which plays an important role in maintaining 
normal bone metabolism [4]. Osteoprotegerin can significantly inhibit the 
differentiation and maturation of osteoclasts and bone resorption activity, and it might 
induce apoptosis and necrosis [5]. Vitamin D (VD) is closely related to the development 
of T2DM and OP. Its main function is to maintain normal blood calcium and 
phosphorus levels and promote normal bone mineralisation [6]. 25-hydroxyvitamin D 
[25(OH)D] is stably present in the body and is a commonly used indicator for the 
observation of VD level. Studies have found that VD receptors are expressed on islet  
cells; VD is involved in glucose metabolism, and VD deficiency impairs human glucose 
regulation and increases the risk of T2DM [7]. Under physiological conditions, VD is 
one of the essential substances for maintaining normal blood sugar and glucose-
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stimulated insulin secretion [8]. The relationship between BSP mRNA expression in 
peripheral blood and 25(OH)D/OPG in type 2 DM (T2DM) patients with different bone 
mass has not been reported in China or abroad. Therefore, this study intended to 
compare the expression of BSP mRNA in peripheral blood of healthy controls with that 
in T2DM patients with different bone masses, in order to explore the possible 
mechanisms of BSP mRNA, 25(OH)D, and OPG in regulating glycometabolism, lipid 
metabolism, and bone mass, thus providing new ideas for early clinical prevention and 
treatment of DM and OP. 
 
Materials and methods 
 
Subjects 
A total of 225 patients hospitalised in the Endocrinology Department and General 
Department from May 2017 to May 2018 were enrolled and categorised into five groups: 
the pure T2DM group (group A, 45 patients), the bone mass reduction group (group B, 
45 patients), the T2DM + bone mass reduction group (group C, 45 patients), the OP 
group (group D, 45 patients), and the T2DM + OP group (group E, 45 patients); 
meanwhile, age/age-matched healthy subjects undergoing physical examination in our 
hospital were collected as the normal control group (group NC, 45 cases). The subjects 
in group NC all had normal bone density and glucose tolerance (by oral glucose 
tolerance test). The T2DM patients were in compliance with the diagnostic criteria of 
WHO Diabetes (1999). Informed consent was obtained from all subjects, and the study 
was approved by the Ethics Committee. 
 
Inclusion criteria 
There were four inclusion criteria: 
1 — females with menopause over one year and males aged ≥ 60 years, meeting the 
criteria for newly diagnosed T2DM;  
2 — without serious organic diseases or acute/chronic complications of diabetes, with 
normal liver and kidney function;  
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3 — the subjects in group NC had no family history of diabetes and osteoporosis;  
4 — without a history of smoking or alcohol abuse. 
 
Exclusion criteria 
There were six exclusion criteria: 
1 — with previous severe heart, liver, kidney, or other organ or endocrine diseases;  
2 — used drugs that may affect sugar, fat, or bone metabolism in the past month;  
3 — with a clear history of infection in the past two weeks;  
4 — suffering from rheumatoid arthritis, thyroid, parathyroid, adrenal gland, gonads, 
bone tumours, pituitary, or other diseases affecting bone metabolism; with fractures;  
5 — used drugs that may affect bone metabolism (sex hormones, bisphosphonates, 
glucocorticoids, high-dose calcium, VD preparations, etc.) in the past six months; 
6 — with a history of smoking or a long history of heavy drinking. 
 
Diagnostic criteria 
The diagnostic criteria for OP refer to the diagnostic criteria for the diagnosis and 
treatment of primary OP issued by the Osteoporosis and Bone Mineral Diseases Society 
of the Chinese Medical Association [9]. According to the DXA measurement results, 
the bone density being lower than and within the standard deviation of bone peak of 
healthy adults with the same sex and race is defined as normal; the reduction ranging 
from 1- to 2.5-fold standard deviation is defined as low bone mass; the reduction 
equalling or more than 2.5-fold standard deviation is defined as OP; the degree of bone 
density reduction meets the diagnostic criteria of OP, and severe OP is defined as OP 
simultaneously combing with one or more fragile fractures. Bone mineral density is 
usually expressed as T-Score, T-score = (measured value – peak bone density of normal 
young people with the same race and gender)/standard deviation of peak bone density 
of normal young people with the same race and gender. The diagnostic criterion of OP 
referring to the bone mineral density of central axis (lumbar vertebrae 1–4, femoral 
neck or total hip) or 1/3 of the distal radius based on DXA measurement is T-score ≤ –
2.5. 
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Collection of general information 
The age and gender of all the study subjects were recorded, together with the height, 
weight, hip circumference, waist circumference, and body mass index (BMI = weight 
[kg]/height2 [m2]). All the above data were imported into the database. 
 
Detection of general blood biochemistry and glucose metabolism indexes 
Each subject was fasted for 12 hours and water-inhibited for eight hours before tests, 
and then sampled fasting venous blood was left standing still for 1 h, separated the 
serum by 10-min centrifugation at 3000 r/min, and stored at –80°C. Real Time PCR 
was used to detect the expression of BSP mRNA (Tab. 1). Fasting plasma insulin (FINS), 
-collagen degradation products (β-CTX), type I-collagen amino end lengthening 
peptide (PINP), and 25(OH)D were determined by electrochemiluminescence (reagents 
were from Roche, German). One Olympus (AU2700) automatic analyser was used for 
detecting blood lipids; the hexokinase method (reagents were from Beckman Coulter 
Experimental System Co., Ltd.) was used for measuring fasting blood glucose (FPG); 
high-performance liquid chromatography (hPLC) was used to determine glycated 
haemoglobin (HbA1c) (reagents were from Bole, USA); homeostasis model of 
assessment for insulin resistance index [HOMA-IR = FPG × FINS/22.5]. 
 
Determination of bone mineral density 
The orthotopic bone mineral density (BMD, expressed in g/cm2) of the lumbar 
vertebrae (L1–4), as well as the BMD of the left and right proximal femur, including 
the femoral neck, greater tubercle, and Ward’s triangle, were measured using a Medix90 
DMS manufactured by MEDILINK, France. 
 
Statistical analysis 
Statistical analysis was performed using SPSS 19.0. The measurement data that 
conformed or were close to the normal distribution were expressed as mean ± standard 
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deviation ( x  ± s). The comparison among multiple groups was analysed by ANOVA. 
The baseline irregularity was treated by covariance. The comparison of two variables 
was performed by line correlation analysis, and Logistic regression analysis was used 
among multiple variables, with p < 0.05 being considered as statistical significance. 
 
Results 
 
Comparison of general data and clinical biochemical indexes  
1. The comparison of age, disease duration, gender, and BMI among groups showed no 
statistical significance (p > 0.05). 
2. Compared with group B, the expression levels of HbA1c, 25(OH)D, PINP, FPG, FINS, 
and HDL-C were significantly increased while OPG and β-CTX were significantly 
decreased in group A (p < 0.05), but the difference in TC, TG, and HOMA-IR was not 
statistically significant (p > 0.05).  
3. Compared with group C, the expressions of PINP, 25(OH)D, and HDL-C were 
significantly increased while OPG, β-CTX, FPG, and HbA1c were significantly 
decreased in group A (p < 0.05), but the difference in TC, TG, FINS, and HOMA-IR 
was not statistically significant (p > 0.05).  
4. Compared with group D, the expression levels of HbA1c, PINP, 25(OH)D, FPG, 
HDL-C, and FINS were significantly increased while OPG and β-CTX were 
significantly decreased in group A (p < 0.05), but the difference in TC, TG, and HOMA-
IR was not significantly different (p > 0.05). 
5. Compared with group D, the expression levels of PINP, 25(OH)D, and HDL-C were 
significantly increased while OPG, β-CTX, FPG, and HbA1c were significantly 
decreased in group A (p < 0.05), but the difference in TC, TG, FINS, and HOMA-IR 
was not statistically significant (p > 0.05).  
6. Compared with group NC, the expression levels of OPG, FPG, HbA1c, HOMA-IR, 
TG, TC, β-CTX, and FINS were significantly increased while the expressions of 
25(OH)D, HDL-C, and PINP were significantly decreased in group A (p < 0.05). 
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7. Compared with group C, the expression levels of PINP, 25(OH)D, and HDL-C were 
significantly increased while OPG, β-CTX, HbA1c, FPG, and FINS were significantly 
decreased in group B (p < 0.05), but the difference in TC, TG, and HOMA-IR was not 
statistically significant (p > 0.05).  
8. Compared with group D, the expression levels of PINP, 25(OH)D, and HDL-C were 
significantly increased while OPG, β-CTX, and HbA1c were significantly decreased in 
group B (p < 0.05), but the difference in TC, TG, FPG, FINS, and HOMA-IR was not 
statistically significant (p > 0.05). 
9. Compared with group E, the expression levels of PINP, 25(OH)D, and HDL-C were 
significantly increased while OPG, β-CTX, HbA1c, FPG, and FINS were significantly 
decreased in group B (p < 0.05), but the difference in TC, TG, and HOMA-IR was not 
statistically significant (p < 0.05). 
10. Compared with group NC, the expression levels of OPG, FPG, HbA1c, HOMA-IR, 
TG, TC, β-CTX, and FINS were significantly increased while the expressions of 
25(OH)D, HDL-C, and PINP were significantly decreased in group B (p < 0.05). 
11. Compared with group D, the expression levels of HbA1c, PINP, 25(OH)D, FPG, 
HDL-C, and FINS were increased significantly while OPG and β-CTX were decreased 
significantly in group C (p < 0.05), but the difference in TC, TG, and HOMA-IR was 
not statistically significant (p > 0.05). 
12. Compared with group E, the expression levels of PINP, 25(OH)D, and HDL-C were 
significantly increased while OPG, β-CTX, FPG, and HbA1c were significantly 
decreased in group C (p < 0.05), but there was no significant difference in TC, TG, 
FINS, and HOMA-IR (p > 0.05). 
13. Compared with group NC, the expression levels of OPG, FPG, HbA1c, HOMA-IR, 
TG, TC, β-CTX, and FINS were significantly increased while 25(OH)D, HDL-C, and 
PINP were significantly decreased in group C (p < 0.05). 
14. Compared with group E, the expression levels of PINP, 25(OH)D, and HDL-C were 
significantly increased while OPG, β-CTX, HbA1c, FPG, and FINS were significantly 
decreased in group D (p < 0.05), but the difference in TC, TG, and HOMA-IR was not 
statistically significant (p > 0.05) 
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15. Compared with group NC, the levels of OPG, FPG, HbA1c, HOMA-IR, TG, TC, β-
CTX, and FINS were significantly increased while 25(OH)D, HDL-C, and PINP were 
significantly decreased in group D (p < 0.05).  
16. Compared with group NC, the expression levels of OPG, FPG, HbA1c, HOMA-IR, 
TG, TC, β-CTX, and FINS were significantly increased while 25(OH)D, HDL-C, and 
PINP were significantly decreased in group E (p < 0.05) (Tab. 2, Fig. 1). 
 
Level of BSP mRNA 
1. Compared with group B, BSP mRNA in the peripheral blood was significantly 
upregulated in group A (p < 0.05). 
2. Compared with group C, BSP mRNA in the peripheral blood was significantly 
upregulated in group A (p < 0.05). 
3. Compared with group D, BSP mRNA in the peripheral blood was significantly 
upregulated in group A (p < 0.05).  
4. Compared with group E, BSP mRNA in the peripheral blood was significantly 
upregulated in group A (p < 0.05).  
5. Compared with group NC, BSP mRNA in the peripheral blood was significantly 
downregulated in group A (p < 0.05).  
6. Compared with group C, BSP mRNA in the peripheral blood was significantly 
upregulated in group B (p < 0.05). 
7. Compared with group D, BSP mRNA in the peripheral blood was significantly 
upregulated in group B (p < 0.05). 
8. Compared with group E, BSP mRNA in the peripheral blood was significantly 
upregulated in group B (p < 0.05). 
9. Compared with group NC, BSP mRNA in the peripheral blood was significantly 
downregulated in group B (p < 0.05).  
10. Compared with group D, BSP mRNA in the peripheral blood was significantly 
upregulated in group C (p < 0.05). 
11. Compared with group E, BSP mRNA in the peripheral blood was significantly 
upregulated in group C (p < 0.05).  
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12. Compared with group NC, BSP mRNA in the peripheral blood was significantly 
downregulated in group C (p < 0.05).  
13. Compared with group E, BSP mRNA in the peripheral blood was significantly 
upregulated in group D (p < 0.05).  
14. Compared with group NC, BSP mRNA in the peripheral blood was significantly 
downregulated in group D (p < 0.05).  
15. Compared with group NC, BSP mRNA in the peripheral blood was significantly 
downregulated in group E (p < 0.05) (Tab. 3, Fig. 2). 
 
Comparison of BMD  
1. The comparison of BMD in the Ward’s triangle and total hip was not statistically 
significant among groups (p > 0.05).  
2. Compared with group B, BMD of L1–L4 and left femoral neck was significantly 
increased in group A (p < 0.05). 
3. Compared with group C, BMD of L1–L4 and left femoral neck was significantly 
increased in group A (p < 0.05). 
4. Compared with group D, BMD of L1–L4 and left femoral neck was significantly 
increased in group A (p < 0.05). 
5. Compared with group E, BMD of L1–L4 and left femoral neck was significantly 
increased in group A (p < 0.05).  
6. Compared with group NC, BMD of L1–L4 and left femoral neck was significantly 
decreased in group A (p < 0.05). 
7. Compared with group C, BMD of L1–L4 and left femoral neck was significantly 
increased in group B (p < 0.05).  
8. Compared with group D, BMD of L1–L4 and left femoral neck was significantly 
increased in group B (p < 0.05).  
9. Compared with group E, BMD of L1–L4 and left femoral neck was significantly 
increased in group B (p < 0.05). 
10. Compared with group NC, BMD of L1–L4 and left femoral neck was significantly 
decreased in group B (p < 0.05). 
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11. Compared with group D, BMD of L1–L4 and left femoral neck was significantly 
increased in group C (p < 0.05). 
12. Compared with group E, BMD of L1–L4 and left femoral neck was significantly 
decreased in group C (p < 0.05).  
13. Compared with group E, BMD of L1–L4 and left femoral neck was significantly 
increased in group D (p < 0.05). 
14. Compared with group NC, BMD of L1–L4 and left femoral neck was significantly 
decreased in group D (p < 0.05). 
15. Compared with group NC, BMD of L1–L4 and left femoral neck was significantly 
decreased in group E (p < 0.05) (Tab. 4).  
 
Results of Pearson correlation analysis 
There was no statistical correlation in the level of BSP mRNA in peripheral blood with 
the age, FPG, BMI, TC, TG, LDL-C, FIns, or HOMA-IR (p > 0.05); the level of BSP 
mRNA in peripheral blood was negatively correlated with β-CTX, HbAlc, and OPG 
(correlation coefficients r were –0.483, –0.474, and –0.527, respectively, p < 0.05) (Tab. 
2); the level of BSP mRNA in peripheral blood was positively correlated with 25(OH)D, 
PINP, and HDL-C (correlation coefficients r were 0.425, 0.477, and 0.626, respectively, 
p < 0.05) (Tab. 5). 
 
Logistic regression analysis of risk factors for initial diagnosis of T2DM with OP 
Setting whether the newly diagnosed T2DM patient was associated with OP as the 
dependent variable, as well as the age, FPG, TC, TG, LDL-C, HDL-C, 25(OH)D, BSP 
mRNA, PINP, β-CTX, HbAlc, HOMA-IR, and OPG as the independent variable, 
multivariate logistic regression analysis was performed targeting the groups. The results 
showed that 25(OH)D, PINP, and HDL-C were the independent protective factors for 
newly diagnosed T2DM patients with OP, but BSP mRNA, β-CTX, HbAlc, and OPG 
were the independent risk factors for newly diagnosed T2DM patients with OP (Tab. 
6). 
Discussion 
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OP is a metabolic bone disease that causes bone fragility and proneness to fracture. Due 
to the increasing incidence in recent years, it has become a major disease that plagues 
the world [10]. T2DM is closely related to OP [11]. In recent years, studies have 
reported that BSP mRNA expression is closely related to DM and OP [12]. However, 
the expression of BSP mRNA in peripheral blood of T2DM patients with different bone 
mass has not been reported in China and abroad. Therefore, this study intended to 
compare the expression of BSP mRNA in peripheral blood of T2DM patients with 
different bone masses with that in healthy controls, aiming to explore the possible 
mechanisms of BSP mRNA, 25(OH)D, and OPG in regulating glycometabolism, lipid 
metabolism, and bone mass, thus providing new ideas for early clinical prevention and 
treatment of DM and OP. 
BSP is a kind of highly glycosylated, phosphorylated, and sulphated non-collagen 
protein containing a large amount of sialic acid and is mainly secreted and expressed 
by osteoblasts, osteoclasts, and cartilage tissue cells. BSP is specifically localised in 
bone tissues and plays a role in regulating the function of bone tissues [13]. Vitamin D 
plays an important role in bone metabolism. The main function of VD is to maintain 
normal blood calcium and phosphorus levels and to promote normal bone 
mineralisation [14]. Because 25(OH)D is relatively high in blood and has a longer half-
life, the level of 25(OH)D is generally clinically determined so as to reflect the VD 
level in humans [15]. Osteoprotegerin plays a specific role in bone tissue and is a key 
determinant factor affecting the differentiation and maturation of osteoclasts, as well as 
regulating bone metabolism [16]. Osteoprotegerin inhibits the differentiation and 
maturation of osteoclasts, prevents excessive bone absorption, and plays a specific role 
in bone protection [17]. Studies have found that the serum OPG level in women aged 
48–65 years is significantly high, indicating that the level in menopausal women is 
higher than that in non-menopausal women. It is speculated that the osteoclast function 
is active when oestrogen is deficient, resulting in bone resorption increase, bone loss 
acceleration, stimulated body compensatory bone formation increase, and 
corresponding increase in serum OPG [18]. -collagen degradation products and PINP 
represent bone resorption and bone formation, respectively, and are commonly used 
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biochemical indicators for reflecting bone transformation [19, 20]. Factors such as 
hyperglycaemia, low HDL-C, hypertension, or endothelial injury can affect the 
expression of BSP mRNA [21]. This study also reveals that plasma 25(OH)D, PINP, 
and HDL-C are positively correlated with the expression of BSP mRNA in peripheral 
blood, but β-CTX, HbAlc, HOMA-IR, and OPG are negatively correlated with BSP 
mRNA expression. With the decrease of bone mass, the levels of BSP mRNA, 25(OH)D, 
PINP, and HDL-C in serum decrease gradually (group NC > group A > group B > group 
C > group D > group E), but the levels of β-CTX and OPG gradually increase (group 
NC < group A < group B < group C < group D < group E), which can presume that 
glucose- and lipid-metabolism disorder, as well as low levels of BSP mRNA and 25 
(OH) D in peripheral blood, can more easily induce OP. Therefore, decreased serum 
VD level, elevated OPG, and decreased expression of BSP mRNA in peripheral blood 
may be risk factors for predicting T2DM with OP. 
 
Conclusions 
Patients with T2DM and OP are often combined with lipid metabolism disorder, 
serum 25(OH)D level reduction, and gradual reduction of BSP mRNA expression in 
peripheral blood, resulting in loss of bone mass; vice versa, bone loss will further 
aggravate glucose- and lipid-metabolism disorder, which forms a vicious circle. 
Therefore, active VD supplementation may break this vicious circle. The decrease of 
25(OH)D in serum may be involved in the development of DM and OP by down-
regulating the expression of BSP mRNA in peripheral blood. Therefore, patients with 
T2DM should not only increase blood glucose control but also pay attention to serum 
25(OH)D and BSP mRNA expression in peripheral blood, which may have a certain 
preventive effect on the prevention and treatment of DM and OP, but its specific 
mechanism needs further research and exploration. 
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Table 1. Specific primers used for real-time polymerase chain reaction (PCR) 
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Primer Primer sequence (5’-3’) 
BSP Upstream 5’-CAACGCCCTGACCACCGATAG-3’ 
Downstream 5’-GGCTGCCTTCCGTCTCATAGT-3’ 
BSP — bone sialoprotein 
 
Table 2. Comparison of general data and biochemical indexes among groups ( x ± s) 
Group 
N 
(M/F) 
Age 
(years) 
BMI 
[kg/m2] 
HbA1c 
(%) 
FPG 
[mmol/L] 
PINP 
[ng/mL] 
OPG 
[ng/L] 
NC 
45 
(25/20) 
63.39 ± 
3.24 
22.33 ± 
2.15 
3.99 ± 
0.35 
4.92 ± 
0.81 
58.02 ± 
12.96 
149.03 ± 
21.02 
A 
45 
(20/25) 
62.52 ± 
2.39 
24.31 ± 
2.31 
8.31 ± 
1.721 
8.82 ± 
2.081 
27.11 ± 
9.931 
180.99 ± 
22.041 
B 
45 
(21/24) 
63.92 ± 
3.98 
23.47 ± 
2.14 
5.41 ± 
1.7312 
6.27 ± 
1.7612 
20.25 ± 
8.6312 
200.53 ± 
23.5312 
C 
45 
(23/22) 
65.82 ± 
4.92 
23.93 ± 
2.71 
9.89 ± 
1.94123 
10.76 ± 
2.021 
14.91 ± 
6.73123 
210.94 ± 
24.72123 
D 
45 
(22/23) 
63.68 ± 
4.32 
23.65 ± 
2.47 
6.09 ± 
1.991234 
6.49 ± 
1.8212 
8.36 ± 
4.841234 
240.93 ± 
27.221234 
E 
45 
(24/21) 
64.18 ± 
3.99 
24.34 ± 
2.83 
14.39 ± 
2.1812345 
12.99 ± 
2.091 
5.03 ± 
3.7512345 
260.94 ± 
25.9912345 
 
Gro
up 
β-
CTX 
[ng/m
L] 
TC 
[mmol
/L] 
TG 
[mmol
/L] 
LDL-
C 
[mmol
/L] 
HDL-
C 
[mmol
/L] 
HOM
A-IR 
25(OH
)D 
[ng/m
L] 
FINS 
[uIU/
mL] 
 
NC 
(n = 
45) 
0.17 ± 
0.11 
4.81 ± 
0.38 
1.23 ± 
0.39 
2.23 ± 
0.42 
1.31 ± 
0.30 
1.98 ± 
0.09 
34.96 
± 2.39 
9.09 ± 
1.81 
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A 
(n = 
45) 
0.52 ± 
0.091 
6.91 ± 
1.311 
3.11 ± 
1.291 
3.42 ± 
0.371 
0.69 ± 
0.231 
5.59 ± 
0.261 
26.43 
± 5.871 
13.01 
± 2.351 
B (n 
= 
45) 
0.68 ± 
0.1912 
7.53 ± 
1.021 
3.32 ± 
1.031 
3.53 ± 
0.631 
0.66 ± 
0.261,2 
3.86 ± 
0.241,2 
20.64 
± 
5.041,2 
10.53 
± 
1.461,2 
C (n 
= 
45) 
0.72 ± 
0.31123 
7.33 ± 
1.311 
3.21 ± 
1.321 
3.58 ± 
0.771 
0.51 ± 
0.321,2,3 
5.62 ± 
0.331 
14.67 
± 
4.241,2,
3 
12.76 
± 1.891 
D 
(n = 
45) 
0.84 ± 
0.33123
4 
6.99 ± 
1.321 
3.26 ± 
1.361 
3.38 ± 
0.471 
0.36 ± 
0.311,2,3
,4 
3.37 ± 
0.2212 
9.96 ± 
4.241,2,
3,4 
10.36 
± 
1.6412 
E 
(n = 
45) 
0.87 ± 
0.421,2,
3,4,5 
7.22 ± 
1.211 
3.12 ± 
1.331 
3.72 ± 
0.441 
0.29 ± 
0.271,2,3
,4,5 
5.05 ± 
0.191 
7.18 ± 
3.841,2,
3,4,5 
12.48 
± 3.031 
Groups: NC — normal control group; A — patients with pure T2DM; B — patients with bone mass 
reduction; C — patients with T2DM + bone mass reduction; D — patients with OP; E — patients with 
T2DM + OP; BMI — body mass index; HbA1c — haemoglobin; FPG — fasting plasma glucose; PINP 
— N-terminal propeptide of type I procollagen; OPG — osteoprotegerin; β-CTX — -collagen 
degradation products; TC — total cholesterol; TG — triglycerides; LDL-C — low-density lipoprotein 
cholesterol; HDL-C — high-density lipoprotein cholesterol; HOMA-IR — homeostasis model of 
assessment for insulin resistance index; 25(OH)D — 25-hydroxyvitamin D; FINS — fasting plasma 
insulin; T2DM — type 2 diabetes mellitus; OP — osteoporosis  
Note: vs. group NC; 1p < 0.05; vs. group A, 2p < 0.05; vs. group B, 3p < 0.05; vs. group C, 4p < 0.05; vs. 
group D, 5p < 0.05 
 
Table 3. Expressions of bone sialoprotein (BSP) mRNA ( x  ± s) 
Group NC A B C D E 
BSP 
mRNA 
4.12 ± 
0.29 
4.02 ± 
0.351 
3.26 ± 
0.651,2 
2.71 ± 
0.751,2,3 
2.01 ± 
0.981,2,3,4 
1.07 ± 
1.111,2,3,4,5 
Groups: NC — normal control group; A — patients with pure T2DM; B — patients with bone mass 
reduction; C — patients with T2DM + bone mass reduction; D — patients with OP; E — patients with 
T2DM + OP 
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Note: vs. group NC,1p < 0.05; vs. group A, 2p < 0.05; vs. group B, 3p < 0.05; vs. group C, 4p < 0.05; vs. 
group D, 5p < 0.05. 
 
Table 4. Comparison of bone mineral density (BMD) among groups 
Group 
L1–L4 
[g/cm2] 
Left femoral 
neck [g/cm2] 
Ward’s triangle 
[g/cm2] 
Total hip 
[g/cm2] 
NC 1.42 ± 0.20 1.27 ± 0.17 0.61 ± 0.13 0.78 ± 0.12 
A 1.33 ± 0.181 1.03 ± 0.131 0.59 ± 0.11 0.75 ± 0.11 
B 1.22 ± 0.141,2 0.97 ± 0.091,2 0.61 ± 0.08 0.80 ± 0.09 
C 0.19 ± 0.111,2,3 0.87 ± 0.071,2,3 0.60 ± 0.09 0.78 ± 0.13 
D 0.88 ± 0.081,2,3,4 0.68 ± 0.061,2,3,4 0.58 ± 0.10 0.81 ± 0.08 
E 0.69 ± 0.061,2,3,4,5 
0.45 ± 
0.051,2,3,4,5 
0.62 ± 0.12 0.79 ± 0.10 
Groups: NC — normal control group; A — patients with pure T2DM; B — patients with bone mass 
reduction; C — patients with T2DM + bone mass reduction; D — patients with OP; E — patients with 
T2DM + OP 
Note: vs. group NC, 1p < 0.05; vs. group A, 2p < 0.05; vs. group B, 3p < 0.05; vs. group C, 4p < 0.05; vs. 
group D, 5p < 0.05 
 
Table 5. Correlative analysis of bone sialoprotein (BSP) mRNA level in peripheral 
blood and clinical biochemical indexes (r) 
Item 
BSP mRNA 
r 
p 
25(OH)D 0.425 0.035 
PINP 0.477 0.041 
HDL-C 0.626 0.036 
OPG –0.527 0.039 
β-CTX –0.483 0.027 
HbAlc –0.474 0.019 
25(OH)D — 25-hydroxyvitamin D; PINP — N-terminal propeptide of type I procollagen; HDL-C — 
high-density lipoprotein cholesterol; OPG — osteoprotegerin; β-CTX — -collagen degradation 
products; HbA1c — haemoglobin 
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Table 6. Logistic regression analysis of risk factors associated with osteoporosis (OP) 
in patients with type 2 diabetes mellitus (T2DM) 
Variable 
Regression 
coefficient 
Wald2 p 
OR 
(95% CI) 
HbA1c (%) 3.162 25.342 0.037 6.632 (2.534–11.546) 
BSP mRNA 7.352 3.353 0.025 7.135 (2.174–9.234) 
β–CTX [ug/L] 3.423 5.097 0.043 4.324 (3.313–7.291) 
OPG [ng/L] 5.211 3.119 0.041 3.391 (1.192–5.273) 
25(OH)D [ng/mL] –0.931 5.128 0.017 0.425 (0.219–0.816) 
PINP [ug/L] –0.169 1.326 0.021 0.226 (0.021–0.332) 
HDL-C [mmol/L] –0.417 2.324 0.039 0.761 (0.012–0.827) 
HbA1c — haemoglobin; BSP — bone sialoprotein; β-CTX — -collagen degradation products; OPG — 
osteoprotegerin; 25(OH)D — 25-hydroxyvitamin D; PINP — N-terminal propeptide of type I 
procollagen; HDL-C — high-density lipoprotein cholesterol  
 
Figure 1A. Comparison of serum levels of 25-hydroxyvitamin D (25[OH]D) among 
groups; B. Comparison of serum osteoprotegerin (OPG) levels among groups 
 
 
 
 
Figure 2 Comparison of expression levels of bone sialoprotein (BSP) mRNA in 
peripheral blood among groups 
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